Patents by Inventor Michel Monod
Michel Monod has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8703444Abstract: The present invention relates to micro-organisms and to methods of producing proteins. More specifically, the inventions relates to a host cell useful for the expression of heterozygous proteins in which the host cell, Pichia pastoris, has been genetically modified so that the gene for endogenous secreted subtilisin Sub2 protease is completely or partially inactivated.Type: GrantFiled: December 13, 2010Date of Patent: April 22, 2014Assignee: Centre Hospitalier Universitaire Vaudois (CHUV)Inventor: Michel Monod
-
Publication number: 20120295307Abstract: The present invention relates to micro-organisms and to methods of producing proteins. More specifically, the inventions relates to a host cell useful for the expression of heterozygous proteins in which the host cell, Pichia pastoris, has been genetically modified so that the gene for endogenous secreted subtilisin Sub2 protease is completely or partially inactivated.Type: ApplicationFiled: December 13, 2010Publication date: November 22, 2012Applicant: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)Inventor: Michel Monod
-
Publication number: 20120276075Abstract: The present invention relates to a novel enzyme composition comprising a prolyl protease and tripeptidyl proteases having unique catalytic properties. The present invention further relates to methods for producing the enzyme composition as well as a pharmaceutical composition and a food supplement containing the enzyme composition and its use in the degradation of polypeptides.Type: ApplicationFiled: December 20, 2010Publication date: November 1, 2012Applicant: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)Inventors: Michel Monod, Eric Grouzmann
-
Patent number: 7943340Abstract: Disclosed herein are fungal nucleic acid sequences that encode novel dipetidyl peptidase IV (DPPIV) polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The aminopeptidase polypeptides, referred to herein as DPPIV proteins of the invention are useful in a variety of medical, research, and commercial applications.Type: GrantFiled: July 3, 2008Date of Patent: May 17, 2011Assignee: Funzyme Biotechnologies SAInventors: Michel Monod, Reto Stocklin, Eric Grouzmann
-
Publication number: 20090130737Abstract: Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.Type: ApplicationFiled: July 3, 2008Publication date: May 21, 2009Applicant: Funzyme Biotechnologies SAInventors: Michel Monod, Reto Stocklin, Eric Grouzmann
-
Patent number: 7468267Abstract: Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.Type: GrantFiled: August 25, 2004Date of Patent: December 23, 2008Assignee: Funzyme Biotechnologies SAInventors: Michel Monod, Reto Stocklin, Eric Grouzmann
-
Patent number: 7354734Abstract: Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.Type: GrantFiled: August 25, 2004Date of Patent: April 8, 2008Assignee: Funzyme Biotechnologies SAInventors: Michel Monod, Reto Stocklin, Eric Grouzmann
-
Publication number: 20070009988Abstract: Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.Type: ApplicationFiled: August 25, 2004Publication date: January 11, 2007Applicant: FUNZYME BIOTECHNOLOGIES SAInventors: Michel Monod, Reto Stocklin, Eric Grouzmann
-
Publication number: 20050158298Abstract: Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein as EXOX nucleic acids and proteins of the invention are useful in a variety of medical, research, and commercial applications.Type: ApplicationFiled: August 25, 2004Publication date: July 21, 2005Inventors: Michel Monod, Reto Stocklin, Eric Grouzmann
-
Patent number: 6709651Abstract: The present invention is directed to methods of treating a wide variety of diseases, disorders and conditions characterized by excessive activity of substance P. The treatment involves administering peptidases that recognize and selectively cleave polypeptides at Xaa-Pro sequences.Type: GrantFiled: July 3, 2001Date of Patent: March 23, 2004Assignee: B.M.R.A. Corporation B.V.Inventors: Eric Grouzmann, Jean-Silvain Lacroix, Michel Monod
-
Publication number: 20030165489Abstract: The present invention is directed to methods of treating mucosal inflammation associated with rhinitis or sinusitis by administering peptidases that recognize and cleave polypeptides at Xaa-Pro sequences. In addition, the invention encompasses therapeutic packages in which pharmaceutical compositions containing the peptidases are preloaded in a device suitable for intranasally delivering drug.Type: ApplicationFiled: November 27, 2001Publication date: September 4, 2003Applicant: B.M.R.A. Corporation B.V.Inventors: Eric Grouzmann, Jean-Silvain Lacroix, Michel Monod
-
Publication number: 20030007965Abstract: The present invention is directed to methods of treating a wide variety of diseases, disorders and conditions characterized by excessive activity of substance P. The treatment involves administering peptidases that recognize and selectively cleave polypeptides at Xaa-Pro sequences.Type: ApplicationFiled: July 3, 2001Publication date: January 9, 2003Inventors: Eric Grouzmann, Jean-Silvain Lacroix, Michel Monod
-
Patent number: 6337069Abstract: The present invention is directed to methods of treating mucosal inflammation associated with rhinitis or sinusitis by administering peptidases that recognize and cleave polypeptides at Xaa-Pro sequences. In addition, the invention encompasses therapeutic packages in which pharmaceutical compositions containing the peptidases are preloaded in a device suitable for intranasally delivering drug.Type: GrantFiled: February 28, 2001Date of Patent: January 8, 2002Assignee: B.M.R.A. Corporation B.V.Inventors: Eric Grouzmann, Jean-Silvain Lacroix, Michel Monod
-
Patent number: 6309868Abstract: The invention has for object the new recombinant prolyl-dipeptidyl-peptidase enzyme (DPP IV) from Aspergillus oryzae comprising the amino-acid sequence from amino acid 1 to amino acid 755 of SEQ ID NO:2 or functional derivatives thereof, and providing a high level of hydrolyzing specificity towards proteins and peptides starting with X-Pro- thus liberating dipeptides of X-Pro type, wherein X is any amino acid. The invention also provides a DNA molecule encoding the enzyme according to the invention, cells expressing the enzyme according to the invention by recombinant technology, an Aspergillus naturally providing a prolyl-dipeptidyl-peptidase activity which has integrated multiple copies of the Aspergillus native promoter which naturally directs the expression of the gene encoding the prolyl-dipeptidyl-peptidase activity, Aspergillus naturally providing a prolyl-dipeptidyl-peptidase activity which is manipulated genetically so that the dppIV gene is inactivated.Type: GrantFiled: March 24, 2000Date of Patent: October 30, 2001Assignee: Nestec S.A.Inventors: Michel Monod, Agnes Doumas, Michael Affolter, Peter Van Den Broek